Neuropathic pain therapeutic - Sphaera Pharma/Synthia Dermatech

Drug Profile

Neuropathic pain therapeutic - Sphaera Pharma/Synthia Dermatech

Alternative Names: diclofenac sodium 1% + triclocarban

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sphaera Pharma
  • Class Non-opioid analgesics
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Neuropathic pain

Most Recent Events

  • 13 Apr 2016 Clinical development is ongoing for Neuropathic pain in India
  • 31 Dec 2009 Sphaera Pharma enters into a collaboration with Synthia Dermatech for development of treatments for Neuropathic pain (Sphaera Pharma website, February 2016) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top